Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (3343)	12/17/2002 6:34:49 PM
From: scaram(o)uche	of 4974

US FDA panel backs Corixa lymphoma drug Bexxar Tuesday December 17, 6:28 pm ET BETHESDA, Md., Dec 17 (Reuters) - A U.S. advisory panel on Tuesday said the experimental cancer drug Bexxar, developed by Corixa Corp. (NasdaqNM:CRXA - News) and Britain's GlaxoSmithKline Plc (London:GSK.L - News), had benefits in treating non-Hodgkin's lymphoma. The Food and Drug Administration advisory committee did not take a formal vote on Bexxar, which is aimed at helping non-Hodgkin's lymphoma patients whose disease has relapsed or become resistant to other treatment. Nevertheless, members of the panel were impressed by Bexxar's data. "It's at least as good, if not better, than what's out there," said James Krook, a cancer specialist from Duluth, Minnesota. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next